4887.T
SAWAI GROUP HOLDINGS Co.,Ltd.
プライム · 医薬品 · 医薬品 · JP
JPY 1,572.50
+0.16%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 200.7B | 201.7B | 189.0B | 176.9B | 200.3B |
| Cost of Revenue | 34.1B | 142.9B | 132.7B | 122.5B | 137.7B |
| Gross Profit | 15.4B | 58.8B | 56.4B | 54.3B | 62.6B |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 6.0B | 26.1B | 23.5B | 23.2B | 30.2B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 26.0M | 4.5B | 17.0B | 456.0M | 272.0M |
| Total Operating Expenses | 6.1B | 30.6B | 40.6B | 23.7B | 30.4B |
| Cost and Expenses | 202.2B | 185.8B | 185.0B | 158.2B | 183.4B |
| Operating Income (EBIT) | (1.5B) | 15.9B | 4.0B | 18.6B | 17.0B |
| Non-Operating | |||||
| Interest Income | 131.0M | 145.0M | 151.0M | 201.0M | 213.0M |
| Interest Expense | 308.0M | 1.8B | 1.0B | 558.0M | 407.0M |
| Net Interest Income | (177.0M) | (1.6B) | (888.0M) | (357.0M) | (194.0M) |
| Other Non-Op Income/Expense | 20.0M | 44.0M | 845.0M | 189.0M | 869.0M |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 6.8B | 14.3B | 3.2B | 18.3B | 16.8B |
| Income Tax Expense | 1.9B | 2.7B | 988.0M | 5.6B | 4.0B |
| Bottom Line | |||||
| Net Income | (2.7B) | 10.4B | 12.0B | 13.7B | 12.7B |
| Earnings from Cont. Ops | 4.9B | 11.5B | 2.2B | 12.7B | — |
| Earnings from Discont. Ops | 35.0M | (1.1B) | 9.8B | (3.5B) | — |
| Bottom Line Net Income | (2.7B) | 10.4B | 12.0B | 9.2B | 12.8B |
| Per Share | |||||
| Basic EPS | (¥16) | ¥90 | ¥97 | ¥313 | ¥289 |
| Diluted EPS | (¥16) | ¥90 | ¥96 | ¥312 | ¥289 |
| Revenue Per Share | ¥1,738 | ¥1,747 | ¥1,525 | ¥4,038 | ¥4,575 |
| Shares | |||||
| Basic Shares Outstanding | 115.5M | 115.5M | 124.0M | 43.8M | 43.8M |
| Diluted Shares Outstanding | — | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | 10.8B | 31.9B | 19.3B | 36.7B | 34.7B |
| D&A | 3.9B | 16.0B | 15.2B | 18.1B | 17.7B |
| EBIT | (1.5B) | 15.9B | 4.0B | 18.6B | 17.0B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026